New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug ...(er commercially available was 73 percent...)

Date:6/12/2009

er commercially available, was 73 percent in agreement with Trofile(TM) . The Quest Diagnostics investigators concluded that the concordance between the two independently developed genotypic tropism tests was comparable to the concordance of each assay with the Trofile, and that the proportion of X4 viruses detected did not vary significantly by assay type.

Quest Diagnostics had offered a prior version of the SensiTrop test through a license with Pathway Diagnostics before acquiring the company during the fourth quarter 2008. The company's new HIV-1 Coreceptor test employs a novel molecular-based technology developed by Quest Diagnostics scientists.

The Quest Diagnostics HIV laboratory testing services menu is the most comprehensive in the diagnostic industry. In addition to HIV tropism testing, the company's test services range from HIV diagnostic testing to monitoring HIV viral load, determining a viral genotype, and testing for the HLA-B*5701 genetic marker as an aid in predicting a hypersensitivity reaction to abacavir (Ziagen(R)), an antiretroviral therapy.

About HIV and AIDS

HIV, or the human immunodeficiency virus, is a retrovirus that infects cells of the human immune system, destroying or impairing their function. The two major viruses that cause AIDS are HIV-1 and HIV-2. The most common, HIV-1, is found worldwide, while HIV-2 is primarily confined to West Africa. The most advanced stage of HIV infection is AIDS, or acquired immunodeficiency syndrome. HIV can take up to 15 years to develop into AIDS, a process that antiretroviral drugs can help delay. The World Health Organization estimates that approximately 1.2 million people over the age of 15 in the U.S. were infected with HIV in 2005, the most recent year for which data is available. HIV antiretroviral therapy (ART) is designed to suppresses or stop HIV disease progression.

About Quest Diagnostics

Qu
'/>"/>

SOURCE Quest Diagnostics Incorporated Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology